Oncoinvent achieved a 50% recruitment milestone in its Phase 2 ovarian cancer study of Radspherin.
Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients
Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients. Radspherin®, the company’s lead product candidate is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities.